ABOS

Acumen Pharmaceuticals, Inc.

Price Chart

Latest Quote

$2.15

-0.14 (-6.11%)

Current Price

Previous Close	$2.29
Open	$2.29
Day High	$2.30
Day Low	$2.12
Volume	319,605

Fetched: 2026-06-06T00:03:17

Stock Information

Shares Outstanding	72.23M
Total Debt	$31.05M
Cash Equivalents	$128.40M
Net Income	$-113.28M
Sector	Healthcare
Industry	Biotechnology
Market Cap	$155.29M
EPS (TTM)	$-1.85
Exchange	NMS

🌐 Visit Website

📊 Comprehensive Analysis

Company Data

Enterprise Value	$68.05M
Income	$-113.28M
Book/sh	$1.21
Cash/sh	$1.78
Employees	60

Financial Ratios

Quick Ratio	4.39
Current Ratio	4.55
Debt/Eq	35.49

Returns & Margins

ROA	-42.37%
ROE	-93.23%

Ownership

Insider Ownership	6.67%
Institutional Ownership	64.09%
Insider & Institutional transactions data not available

Valuation Ratios

Forward P/E	-1.43
P/B	1.78

Analyst Data

Recommendation	strong_buy
Target Price	$7.40

Technical Indicators

SMA20	$2.41
SMA50	$2.50
SMA200	$2.19
RSI	44.44
ATR	0.1506

Shares Float	37.01M
Short Float	3.47%
Short Ratio	5.77
Rel Volume	0.99

Performance History

Week	-17.31%
Month	-16.34%
Quarter	-35.05%
6 Months	+11.40%
YTD	+6.44%
Year	+100.93%
3 Years	-56.39%
10 Years	-89.30%

Stock Score: ⭐ Premium

Based on debt, profitability, growth, and cash flow metrics

⭐ Premium Feature

Recent Price History

Date	Close	Volume
2026-06-05	$2.15	319,605
2026-06-04	$2.29	334,600
2026-06-03	$2.29	299,900
2026-06-02	$2.37	265,900
2026-06-01	$2.51	427,100
2026-05-29	$2.60	189,600
2026-05-28	$2.54	266,400
2026-05-27	$2.54	287,000
2026-05-26	$2.42	303,600
2026-05-22	$2.51	396,200
2026-05-21	$2.49	412,900
2026-05-20	$2.35	343,000
2026-05-19	$2.17	440,000
2026-05-18	$2.18	494,300
2026-05-15	$2.28	390,200
2026-05-14	$2.39	262,800
2026-05-13	$2.49	177,900
2026-05-12	$2.48	250,200
2026-05-11	$2.57	430,400
2026-05-08	$2.56	163,300
2026-05-07	$2.47	328,300
2026-05-06	$2.57	264,300

About Acumen Pharmaceuticals, Inc.

Acumen Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops targeted therapies for the treatment of Alzheimer's disease. It focuses on advancing a targeted immunotherapy drug candidate, sabirnetug (ACU193), which is in its Phase 2 ALTITUDE-AD clinical trial to target toxic soluble amyloid beta oligomers. Acumen Pharmaceuticals, Inc. has a collaboration and license agreement with Halozyme, Inc. for the development of a subcutaneous formulation of Sabirnetug, as well as with JCR Pharmaceuticals Co. Ltd for the development of Aß oligomer-targeted enhanced brain delivery therapy for the treatment of Alzheimer's disease. The company was incorporated in 1996 and is headquartered in Newton, Massachusetts.

📰 Latest News

Acumen Pharmaceuticals Inc (ABOS) Q1 2026 Earnings Call Highlights: Strategic Advances Amid ...

GuruFocus.com • 2026-05-12T19:01:22Z

Acumen Pharmaceuticals Q1 Earnings Call Highlights

MarketBeat • 2026-05-12T13:07:32Z

Acumen Pharmaceuticals (ABOS) Loses 33.6% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner

Zacks • 2026-03-31T13:35:02Z

Is Acumen Pharmaceuticals (ABOS) Stock Outpacing Its Medical Peers This Year?

Zacks • 2026-03-30T13:40:02Z

Acumen Pharmaceuticals, Inc. Q4 2025 Earnings Call Summary

Moby • 2026-03-27T12:30:00Z

Acumen Pharmaceuticals Inc (ABOS) Q4 2025 Earnings Call Highlights: Strategic Advances Amid ...

GuruFocus.com • 2026-03-26T19:00:45Z

Acumen Pharmaceuticals Q4 Earnings Call Highlights

MarketBeat • 2026-03-26T14:07:15Z

Acumen Pharmaceuticals Spotlights Sabirnetug Phase II Progress, JCR Brain-Delivery Partnership at Conference

MarketBeat • 2026-03-19T00:11:14Z

Acumen Pharma Presents Brain Delivery Studies at Alzheimer’s and Parkinson’s Diseases Conference 2026

Exec Edge • 2026-03-17T21:41:21Z

Assessing Acumen Pharmaceuticals (ABOS) Valuation After New Phase 2 ALTITUDE-AD Trial Developments

Simply Wall St. • 2026-01-28T02:08:17Z

Period:

Income Statement (Annual)

Metric	2025-12-31	2024-12-31	2023-12-31	2022-12-31
Revenue
Total Revenue	$0	$0	$0	$0
Operating Revenue	$0	$0	$0	$0
Expenses
Interest Expense	$4,224,000	$4,068,000	$581,000	$0
Total Expenses	$123,832,000	$114,017,000	$61,138,000	$45,237,000
Other Income Expense	$-726,000	$1,439,000	$-1,443,000	$-11,000
Other Non Operating Income Expenses	$-266,000	$-151,000	$-83,000	$-11,000
Net Non Operating Interest Income Expense	$3,223,000	$10,249,000	$10,210,000	$2,392,000
Interest Expense Non Operating	$4,224,000	$4,068,000	$581,000	$0
Operating Expense	$123,832,000	$114,017,000	$61,138,000	$45,237,000
General And Administrative Expense	$18,947,000	$20,219,000	$18,820,000	$12,876,000
Income & Earnings
Net Income From Continuing Operation Net Minority Interest	$-121,335,000	$-102,329,000	$-52,371,000	$-42,856,000
Net Interest Income	$3,223,000	$10,249,000	$10,210,000	$2,392,000
Interest Income	$7,447,000	$14,317,000	$10,791,000	$2,392,000
Normalized Income	$-120,875,000	$-103,919,000	$-51,011,000	$-42,856,000
Net Income From Continuing And Discontinued Operation	$-121,335,000	$-102,329,000	$-52,371,000	$-42,856,000
Total Operating Income As Reported	$-123,832,000	$-114,017,000	$-61,138,000	$-45,237,000
Net Income Common Stockholders	$-121,335,000	$-102,329,000	$-52,371,000	$-42,856,000
Net Income	$-121,335,000	$-102,329,000	$-52,371,000	$-42,856,000
Net Income Including Noncontrolling Interests	$-121,335,000	$-102,329,000	$-52,371,000	$-42,856,000
Net Income Continuous Operations	$-121,335,000	$-102,329,000	$-52,371,000	$-42,856,000
Pretax Income	$-121,335,000	$-102,329,000	$-52,371,000	$-42,856,000
Interest Income Non Operating	$7,447,000	$14,317,000	$10,791,000	$2,392,000
Operating Income	$-123,832,000	$-114,017,000	$-61,138,000	$-45,237,000
Per Share
Diluted EPS	$-2.00	$-1.71	$-1.08	$-1.06
Basic EPS	$-2.00	$-1.71	$-1.08	$-1.06
Other
Tax Effect Of Unusual Items	$0	$0	$0	$0
Tax Rate For Calcs	$0	$0	$0	$0
Normalized EBITDA (Bullshit earnings)	$-116,467,000	$-99,673,000	$-50,246,000	$-42,687,000
Total Unusual Items	$-460,000	$1,590,000	$-1,360,000	-
Total Unusual Items Excluding Goodwill	$-460,000	$1,590,000	$-1,360,000	-
Reconciled Depreciation	$184,000	$178,000	$184,000	$169,000
EBITDA (Bullshit earnings)	$-116,927,000	$-98,083,000	$-51,606,000	$-42,687,000
EBIT	$-117,111,000	$-98,261,000	$-51,790,000	$-42,856,000
Diluted Average Shares	$60,561,836	$60,013,277	$48,609,383	$40,601,936
Basic Average Shares	$60,561,836	$60,013,277	$48,609,383	$40,601,936
Diluted NI Availto Com Stockholders	$-121,335,000	$-102,329,000	$-52,371,000	$-42,856,000
Gain On Sale Of Security	$-460,000	$1,590,000	$-1,360,000	-
Research And Development	$104,885,000	$93,798,000	$42,318,000	$32,361,000
Selling General And Administration	$18,947,000	$20,219,000	$18,820,000	$12,876,000
Other Gand A	$18,947,000	$20,219,000	$18,820,000	$12,876,000

Fetched: 2026-06-02

Balance Sheet (Annual)

Metric	2025-12-31	2024-12-31	2023-12-31	2022-12-31
Assets
Net Tangible Assets	$70,401,000	$181,741,000	$266,804,000	$188,775,000
Total Assets	$122,833,000	$238,992,000	$310,125,000	$196,587,000
Total Non Current Assets	$581,000	$60,686,000	$63,510,000	$16,258,000
Other Non Current Assets	$309,000	$304,000	$243,000	$151,000
Non Current Prepaid Assets	$0	$0	$42,000	-
Investmentin Financial Assets	$0	$59,968,000	$62,553,000	$15,837,000
Goodwill And Other Intangible Assets	$29,000	$75,000	$169,000	-
Other Intangible Assets	$29,000	$75,000	$169,000	-
Current Assets	$122,252,000	$178,306,000	$246,615,000	$180,329,000
Other Current Assets	$4,161,000	$5,546,000	$1,963,000	$1,419,000
Prepaid Assets	$601,000	$858,000	$905,000	$1,305,000
Receivables	$625,000	$345,000	$225,000	$0
Other Receivables	$625,000	$345,000	-	-
Cash Cash Equivalents And Short Term Investments	$116,865,000	$171,557,000	$243,522,000	$177,605,000
Cash And Cash Equivalents	$53,989,000	$35,627,000	$66,886,000	$130,101,000
Accrued Interest Receivable	-	$53,000	$225,000	$0
Debt
Total Debt	$31,311,000	$28,732,000	$28,487,000	$105,000
Long Term Debt And Capital Lease Obligation	$22,396,000	$28,599,000	$27,621,000	$0
Long Term Debt	$22,396,000	$28,449,000	$27,337,000	-
Current Debt And Capital Lease Obligation	$8,915,000	$133,000	$866,000	$105,000
Current Debt	$8,765,000	-	-	-
Other Current Borrowings	$8,765,000	-	-	-
Liabilities
Total Liabilities Net Minority Interest	$52,403,000	$57,176,000	$43,152,000	$7,812,000
Total Non Current Liabilities Net Minority Interest	$22,396,000	$29,569,000	$30,181,000	$0
Current Liabilities	$30,007,000	$27,607,000	$12,971,000	$7,812,000
Other Current Liabilities	$180,000	$230,000	$212,000	$131,000
Payables And Accrued Expenses	$16,846,000	$23,037,000	$8,201,000	$5,568,000
Interest Payable	$249,000	$249,000	$249,000	$0
Payables	$554,000	$5,648,000	$1,379,000	$1,640,000
Accounts Payable	$554,000	$5,648,000	$1,379,000	$1,640,000
Derivative Product Liabilities	-	$970,000	$2,560,000	-
Equity
Common Stock Equity	$70,430,000	$181,816,000	$266,973,000	$188,775,000
Total Equity Gross Minority Interest	$70,430,000	$181,816,000	$266,973,000	$188,775,000
Stockholders Equity	$70,430,000	$181,816,000	$266,973,000	$188,775,000
Gains Losses Not Affecting Retained Earnings	$83,000	$-48,000	$312,000	$-751,000
Other Equity Adjustments	$83,000	$-48,000	$312,000	$-751,000
Retained Earnings	$-446,462,000	$-325,127,000	$-222,798,000	$-170,427,000
Preferred Securities Outside Stock Equity	-	-	-	$0
Other
Ordinary Shares Number	$60,575,369	$60,094,083	$57,910,461	$41,025,062
Share Issued	$60,575,369	$60,094,083	$57,910,461	$41,025,062
Tangible Book Value	$70,401,000	$181,741,000	$266,804,000	$188,775,000
Invested Capital	$101,591,000	$210,265,000	$294,310,000	$188,775,000
Working Capital	$92,245,000	$150,699,000	$233,644,000	$172,517,000
Capital Lease Obligations	$150,000	$283,000	$1,150,000	$105,000
Total Capitalization	$92,826,000	$210,265,000	$294,310,000	$188,775,000
Additional Paid In Capital	$516,803,000	$506,985,000	$489,453,000	$359,949,000
Capital Stock	$6,000	$6,000	$6,000	$4,000
Common Stock	$6,000	$6,000	$6,000	$4,000
Preferred Stock	$0	$0	$0	$0
Current Capital Lease Obligation	$150,000	$133,000	$866,000	$105,000
Pensionand Other Post Retirement Benefit Plans Current	$4,066,000	$4,207,000	$3,692,000	$2,008,000
Current Accrued Expenses	$16,292,000	$17,389,000	$6,822,000	$3,928,000
Investments And Advances	$0	$59,968,000	$62,553,000	$15,837,000
Net PPE	$243,000	$339,000	$503,000	$270,000
Gross PPE	$243,000	$339,000	$503,000	$270,000
Other Properties	$243,000	$339,000	$503,000	$270,000
Other Short Term Investments	$62,876,000	$135,930,000	$176,636,000	$47,504,000
Employee Benefits	-	$0	$0	-
Long Term Capital Lease Obligation	-	$150,000	$284,000	$0
Available For Sale Securities	-	$59,968,000	$62,553,000	$15,837,000
Treasury Shares Number	-	-	$0	-

Fetched: 2026-06-02

Cash Flow Statement (Annual)

Metric	2025-12-31	2024-12-31	2023-12-31	2022-12-31
Free Cash Flow
Free Cash Flow	$-115,626,000	$-86,231,000	$-43,085,000	$-35,314,000
Operating Activities
Operating Cash Flow	$-115,538,000	$-86,215,000	$-43,064,000	$-35,153,000
Cash Flow From Continuing Operating Activities	$-115,538,000	$-86,215,000	$-43,064,000	$-35,153,000
Operating Gains Losses	$401,000	$-1,687,000	$1,349,000	-
Investing Activities
Capital Expenditure	$-88,000	$-16,000	$-21,000	$-161,000
Investing Cash Flow	$133,933,000	$48,027,000	$-171,671,000	$39,185,000
Cash Flow From Continuing Investing Activities	$133,933,000	$48,027,000	$-171,671,000	$39,185,000
Financing Activities
Repurchase Of Capital Stock	$-73,000	$-41,000	$0	-
Issuance Of Capital Stock	$0	$7,938,000	$121,904,000	$3,792,000
Financing Cash Flow	$-34,000	$6,928,000	$151,753,000	$3,907,000
Cash Flow From Continuing Financing Activities	$-34,000	$6,928,000	$151,753,000	$3,907,000
Net Common Stock Issuance	$-73,000	$7,897,000	$121,904,000	$3,792,000
Common Stock Issuance	$0	$7,938,000	$121,904,000	$3,792,000
Net Other Financing Charges	-	$-230,000	$-476,000	-
Cash Dividends Paid	-	$0	$0	-
Net Preferred Stock Issuance	-	-	-	$0
Preferred Stock Issuance	-	-	-	$0
Other
Repayment Of Debt	$0	$-739,000	$0	-
Interest Paid Supplemental Data	$2,936,000	$2,973,000	$169,000	$0
Income Tax Paid Supplemental Data	$0	$0	$0	$0
End Cash Position	$54,220,000	$35,859,000	$67,119,000	$130,101,000
Beginning Cash Position	$35,859,000	$67,119,000	$130,101,000	$122,162,000
Changes In Cash	$18,361,000	$-31,260,000	$-62,982,000	$7,939,000
Proceeds From Stock Option Exercised	$39,000	$0	$325,000	$115,000
Common Stock Payments	$-73,000	$-41,000	$0	-
Net Issuance Payments Of Debt	$0	$-739,000	$30,000,000	$0
Net Long Term Debt Issuance	$0	$-739,000	$30,000,000	$0
Long Term Debt Payments	$0	$-739,000	$0	-
Net Investment Purchase And Sale	$134,021,000	$48,043,000	$-171,653,000	$39,346,000
Sale Of Investment	$172,077,000	$218,774,000	$78,981,000	$80,860,000
Purchase Of Investment	$-38,056,000	$-170,731,000	$-250,634,000	$-41,514,000
Net PPE Purchase And Sale	$-88,000	$-16,000	$-18,000	$-161,000
Purchase Of PPE	$-88,000	$-16,000	$-21,000	$-161,000
Change In Working Capital	$-5,119,000	$11,653,000	$3,866,000	$3,986,000
Change In Other Current Liabilities	$0	$-23,000	$17,000	$-137,000
Change In Other Current Assets	$40,000	$74,000	$-70,000	$-137,000
Change In Payables And Accrued Expense	$-6,521,000	$15,258,000	$4,288,000	$2,560,000
Change In Accrued Expense	$-1,427,000	$10,989,000	$4,549,000	$2,008,000
Change In Payable	$-5,094,000	$4,269,000	$-261,000	$552,000
Change In Account Payable	$-5,094,000	$4,269,000	$-261,000	$552,000
Change In Prepaid Assets	$1,362,000	$-3,656,000	$-369,000	$1,700,000
Other Non Cash Items	$1,288,000	$1,350,000	$884,000	-
Stock Based Compensation	$9,852,000	$9,635,000	$6,145,000	$3,061,000
Amortization Of Securities	$-809,000	$-5,015,000	$-3,121,000	$487,000
Depreciation Amortization Depletion	$184,000	$178,000	$184,000	$169,000
Depreciation And Amortization	$184,000	$178,000	$184,000	$169,000
Depreciation	$184,000	$178,000	$184,000	$169,000
Gain Loss On Investment Securities	$401,000	$-1,687,000	$1,349,000	-
Net Income From Continuing Operations	$-121,335,000	$-102,329,000	$-52,371,000	$-42,856,000
Issuance Of Debt	-	$0	$30,000,000	$0
Interest Paid Cff	-	$0	$-476,000	-
Long Term Debt Issuance	-	$0	$30,000,000	$0
Sale Of PPE	-	$0	$3,000	$0
Change In Receivables	-	-	-	-

Fetched: 2026-06-02